UCLA Jonsson Comprehensive Cancer Center

Radiation oncologist who showed MRI-guided prostate radiotherapy causes fewer side effects.

Melanoma immunotherapy leader behind pembrolizumab's first trials and the science of why immunotherapy fails.

In 1992 she was the first patient with recurrent HER2-positive breast cancer to be treated with the antibody that became Herceptin, in Dennis Slamon's trial at UCLA. She became its first long-term survivor.

Linked HER2 amplification to aggressive breast cancer and drove trastuzumab and later palbociclib to approval.

Runs the UCLA theranostics trials that test PSMA imaging against conventional scans and lutetium against chemotherapy.

Nuclear medicine leader who helped bring PSMA PET and radioligand therapy to the United States.

Michael Teitell is a pathologist and cancer biologist who directs UCLA's cancer centre.

Discovered the BCR-ABL kinase activity that imatinib blocks and now hunts for new prostate cancer targets.

Her Breast Book gave women the information to question their surgeons; she co-founded the National Breast Cancer Coalition and in 2008 recruited hundreds of thousands of women into research through the Army of Women.